Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool

por McChalicher, Christopher W J, Lombardo, Mary-Jane, Khanna, Sahil, McKenzie, Gregory J, Halvorsen, Elizabeth M, Almomani, Sanabel, Schuster, Brian, Hasson, Brooke R, McGovern, Barbara H, Ege, David S, Auniņš, John G
Publicado 2023

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

por McGovern, Barbara H, Ford, Christopher B, Henn, Matthew R, Pardi, Darrell S, Khanna, Sahil, Hohmann, Elizabeth L, O’Brien, Edward J, Desjardins, Christopher A, Bernardo, Patricia, Wortman, Jennifer R, Lombardo, Mary-Jane, Litcofsky, Kevin D, Winkler, Jonathan A, McChalicher, Christopher W J, Li, Sunny S, Tomlinson, Amelia D, Nandakumar, Madhumitha, Cook, David N, Pomerantz, Roger J, Auninš, John G, Trucksis, Michele
Publicado 2020